The persistence of Helicobacter pylori infections despite decades of treatment protocols signals a critical shift in how clinicians must approach this widespread pathogen. New resistance patterns are forcing gastroenterologists to abandon previously reliable therapeutic approaches, potentially affecting millions who carry this infection unknowingly. The American College of Gastroenterology's 2024 guidelines represent a strategic pivot away from traditional triple therapy regimens that have become increasingly ineffective. The updated protocols emphasize bismuth-based quadruple therapy and clarithromycin-free combinations as first-line treatments, acknowledging that resistance to key antibiotics like clarithromycin now exceeds 15% in many regions. These recommendations also expand testing criteria and introduce more aggressive eradication verification protocols. The clinical implications extend far beyond immediate gastric symptoms. H. pylori eradication significantly reduces gastric cancer risk—the third leading cause of cancer death globally—making successful treatment a longevity intervention rather than merely symptom management. The bacterium's role in iron deficiency anemia, vitamin B12 malabsorption, and potentially cardiovascular health creates cascading effects throughout multiple body systems. However, these guidelines face implementation challenges in real-world settings where antibiotic susceptibility testing remains limited and patient compliance with complex multi-drug regimens varies significantly. The shift toward more sophisticated treatment algorithms reflects the evolving understanding of antibiotic stewardship in an era of increasing microbial resistance, positioning H. pylori treatment as a bellwether for broader infectious disease management strategies.